Developed by scientists at Cerba Healthcare on nasopharyngeal ongoing patient samples, these tools are available and efficient on clinical specimens.
Furthermore, this whole-genome sequencing in NGS assay is available for other viruses responsible for respiratory diseases like influenza viruses.
The developments reinforce Cerba Healthcare and Cerba Research's scientific commitment to the continued fight against the pandemic.
Cerba Research recently announced its In Vitro Diagnostic division supported The French Public Health Agency (Santé Publique France) in a prospective COVID-19 seroprevalence study now identified as a major partner for epidemiological studies with the French government.
Cerba Research is a healthcare diagnostic company with end-to-end drug development and diagnostic solutions to optimize R and D drug productivity and commercialization.
Providing global clinical trial central laboratory solutions (speciality lab, FCM, ICH, NGS, BioA, metabolomics), translational science (biomarkers development, CDx, biobanking), and IVD (biospecimens, prospective and retrospective sample collection, IVD evaluation).
Cerba Healthcare, the parent company of Cerba Research, is an international network of medical biology laboratories that offers a complete solution in terms of biological diagnostics, ranging from the collection centre to the speciality laboratory.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review